Opinion statement
Therapy for Whipple’s disease should be continued for a minimum of 1 year, and the regimen should include an agent or agents that achieve acceptable concentrations in the central nervous system, given the likelihood of recurrence at this site. Clinical follow-up of proven cases of Whipple’s disease should be conducted for a minimum of 10 years after discontinuation of therapy, given the potential for late relapses. Polymerase chain reaction analysis is preferred rather than endoscopy when evaluating for disease recurrence.
Similar content being viewed by others
References and Recommended Reading
Durand DV, Lecomte C, Cathebras P, et al.: Whipple’s disease: clinical review of 52 cases. Medicine 1997, 6:170–184.Important review of clinical manifestations.
Dobbins WO: Whipple’s Disease. Springfield, IL: Charles C Thomas, 1987.
Marth T: Whipple’s disease. In Principles and Practice of Infectious Diseases, edn 5. Edited by Mandell GI, Dolin R, Bennett JE. Philadelphia: Churchill Livingstone; 1999:1170–1174.
Misbah SA, Ozols B, Franks A, et al.: Whipple’s disease without malabsorption: new atypical features. Q J Med 1997, 90:765–772.
Ehrbar H,Bauerfiend P, Dutly H, et al.: PCR positive tests for Tropheryma whippelei in patients without Whipple’s disease. Lancet 1999, 353:2214.
Singer R: Diagnosis and treatment of Whipple’s disease [review]. Drugs1998, 55:699–704.
Flemming JL, Wiesner RH, Shorter RG: Whipple’s disease: clinical, biochemical and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc 1988, 63:539–551.
Ratnaike RN: Whipple’s disease. Postgrad Med J 2000, 76:760–766.
Ramzan NN, Loftus E, Burgart LJ, et al.: Diagnosis and monitoring of Whipple’s disease by polymerase chain reaction. Ann Intern Med 1997, 126:520–527. This article compares the use of PCR with conventional histopathologic review to diagnose and monitor WD with gastrointestinal and CNS involvement.
Keinath RD, Merrell DE, Vlietstra R, et al.: Antibiotic treatment and relapse in Whipple’s disease. Longterm follow-up of 88 patients. Gastroenterology 1985, 88:1867–1873.
Schneider T, Stallmack A, von Herbay G, et al.: Successful treatment of refractory Whipple’s disease with adjunctive interferon gamma treatment [abstract]. Gastroenterology 1997, 112:1085. This article contains a review of symptoms of WD with cerebral involvement in patients receiving TMP/SMX.s
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Flemmer, M.C., Flenner, R.W. Current insights in Whipple’s disease. Curr Treat Options Gastro 6, 13–16 (2003). https://doi.org/10.1007/s11938-003-0028-3
Issue Date:
DOI: https://doi.org/10.1007/s11938-003-0028-3